Abstract:Purpose Melanoma is a malignant tumor and causes majority of deaths related to skin cancer. Fibroblast growth factor 2 (FGF2) greatly contributes to melanoma growth and progress. In this paper, we attempt to evaluate the therapeutic potential of FGF2-binding peptide (named P7) using as a potent FGF2 antagonist via exploration of its antitumor effect on melanoma in vitro and in vivo. Methods Cell viability was measured by WST-1. Cell cycle progression was determined by propidium iodide staining and flow cytometry. Western blotting was carried out to detect the activation of Erk1/2, P38, Akt, and MEK, and the expression of apoptosis-associated proteins. The influence of P7 on FGF2 internalization was assessed by separation of nuclear and cytoplasmic protein fractions followed by Western blotting. Female C57BL/6 mice bearing xenograft melanoma were established and used to evaluate the antitumor effect of P7 in vivo. Results In this study, we first proved that P7 peptides significantly inhibited proliferation of FGF2-induced melanoma cell line B16-F10. Further investigations revealed that the mechanisms of P7 peptides inhibiting cell proliferation of melanoma cells stimulated with FGF2 in vitro involved cell cycle arrest at the G0/G1 phase, blockade of the activation of Erk1/2, P38, and Akt cascades, and inhibition of FGF2 internalization. Finally, treatment of P7 peptides in a murine melanoma model resulted in significant inhibition of tumor growth and angiogenesis in vivo, which was associated with blockade of mitogen-activated protein kinase signal activation, and suppression of the expressions of anti-apoptotic Bcl-2 protein and angiogenic factor in the melanoma tumors. Conclusions The FGF2-binding peptide with potent antiproliferation and anti-angiogenic activity may have therapeutic potential in melanoma.

Effects of a Synthetic Bfgf Antagonist Peptide on the Proteome of 3T3 Cells Stimulated with Bfgf

[Mechanism of Inhibitory Effect of P7 on 3T3 Cell Proliferation Induced by Basic Fibroblast Growth Factor].

Anti-Proliferation Effect of a Short Peptide on Bfgf-Induced Human Gastric Cancer Cells

A Novel Bfgf Antagonist Peptide Inhibits Breast Cancer Cell Growth.

Proteomics Approach to Investigate Impact of Afgf Antagonist on Signal Transduction Pathway

P7 Peptides Suppress the Proliferation of K562 Cells Induced by Basic Fibroblast Growth Factor

Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity.

A bFGF Antagonist Peptide with Anti-angiogenesis Properties in Non-small Cell Lung Cancer Cells

Inhibition of Proliferation of Non-small Cell Lung Cancer Cells by a Bfgf Antagonist Peptide

Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation.

P7 Peptides Targeting Bfgf Sensitize Colorectal Cancer Cells to CPT-11.

Activity Study of Specific Bfgf-Binding Phage

A novel FGF2 antagonist peptide P8 with potent antiproliferation activity

Mechanism of Bfgf-Binding Peptide Reversing Adriamycin Resistance in Human Gastric Cancer Cells

The FGF2-binding Peptide P7 Inhibits Melanoma Growth in Vitro and in Vivo

The Design, Characterizations, and Tumor Angiogenesis Inhibition of a Multi-Epitope Peptibody with Bfgf/vegfa

Identification of a Novel Afgf-Binding Peptide with Anti-Tumor Effect on Breast Cancer from Phage Display Library

A Peptide Derivative Serves As A Fibroblast Growth Factor 2 Antagonist in Human Gastric Cancer

The Biopanning and Appraisal of Key Sequence of Transforming Growth Factor-beta 1

A Short Peptide Derived from the Gn Helix Domain of Fgf8b Suppresses the Growth of Human Prostate Cancer Cells

Antitumor Effect of F-Pbf Beta-Trcp-Induced Targeted Pttg1 Degradation in Hela Cells